Page 48 - Read Online

Matrone et al. J Cancer Metastasis Treat 2021;7:23 https://dx.doi.org/10.20517/2394-4722.2021.47 Page 15 of 19

Copyright
©The Author(s) 2021.

REFERENCES
1. Melvin KE, Tashjian AH Jr. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proc Natl
Acad Sci U S A 1968;59:1216-22. DOI PubMed PMC
2. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab
1959;19:152-61. DOI PubMed
3. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral
study using six separate antigens. Am J Clin Pathol 1991;95:300-8. DOI PubMed
4. Gmunder-Lehner RB, Okamoto E, Hedinger C. Distribution of C cells in the human thyroid gland. Schweiz Med Wochenschr
1983;113:1385-94. PubMed
5. Available from: https://rarediseases.info.nih.gov/diseases/7004/thyroid-cancer-medullary. [Last accessed on 20 Apr 2021].
6. Bergholm U, Adami HO, Telenius-Berg M, Johansson H, Wilander E. Incidence of sporadic and familial medullary thyroid
carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncol 1990;29:9-15.
DOI PubMed
7. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol
Head Neck Surg 2003;128:115-23. DOI PubMed
8. Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmö, Sweden. Cancer 1981;47:319-23. DOI PubMed
9. Christensen SB, Ljungberg O, Tibblin S. A clinical epidemiologic study of thyroid carcinoma in Malmö, Sweden. Curr Probl Cancer
1984;8:1-49. DOI PubMed
10. Romei C, Pardi E, Cetani F, Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J Oncol
2012;2012:705036. DOI PubMed PMC
11. Elisei R, Matrone A, Valerio L, et al. Fifty years after the first description, MEN 2B syndrome diagnosis is still late: descriptions of
two recent cases. J Clin Endocrinol Metab 2019;104:2520-6. DOI PubMed
12. Sanso GE, Domene HM, Garcia R, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive
thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer
2002;94:323-30. DOI PubMed
13. Niccoli-Sire P, Murat A, Baudin E, et al. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71
thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). Eur J Endocrinol 1999;141:468-74. DOI PubMed
14. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med
2003;349:1517-25. DOI PubMed
15. Elisei R, Tacito A, Ramone T, et al. Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the
prevalence of germline RET mutations. Genes (Basel) 2019;10:698. DOI PubMed PMC
16. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet
1993;2:851-6. DOI PubMed
17. Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the
International RET Mutation Consortium. J Intern Med 1995;238:343-6. DOI PubMed
18. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Nature 1993;363:458-60. DOI PubMed
19. Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev
Endocrinol 2016;12:192-202. DOI PubMed
20. Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid
carcinomas studied by next-generation targeted sequencing. iScience 2019;20:324-36. DOI PubMed PMC
21. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:
a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7. DOI PubMed
22. Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat
Rev Endocrinol 2017;13:644-60. DOI PubMed
23. Christensen SB, Ljungberg O. Mortality from thyroid carcinoma in malmö, Sweden 1960–1977. A clinical and pathologic study of 38
fatal cases. Cancer 1984;54:1629-34. DOI PubMed
24. Kwon H, Kim WG, Sung TY, et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid
carcinoma. J Surg Oncol 2016;113:152-8. DOI PubMed
25. Torresan F, Mian C, Cavedon E, Iacobone M. Cure and survival of sporadic medullary thyroid carcinoma following systematic
preoperative calcitonin screening. Langenbecks Arch Surg 2019;404:411-9. DOI PubMed
26. Torresan F, Cavedon E, Mian C, Iacobone M. Long-term outcome after surgery for medullary thyroid carcinoma: a single-center
experience. World J Surg 2018;42:367-75. DOI PubMed
27. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and
prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-10. DOI PubMed
28. Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Survival and long-term biochemical cure in medullary thyroid carcinoma in
denmark 1997-2014: a nationwide study. Thyroid 2019;29:368-77. DOI PubMed PMC